Billiontoone (NASDAQ:BLLN) Reaches New 52-Week Low – Time to Sell?

Billiontoone, Inc. (NASDAQ:BLLN) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $64.74 and last traded at $65.7970, with a volume of 164184 shares. The stock had previously closed at $70.20.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. cut their price target on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Wednesday, December 10th. Piper Sandler reaffirmed an “overweight” rating on shares of Billiontoone in a report on Wednesday, December 10th. Wells Fargo & Company dropped their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Finally, Guggenheim restated a “buy” rating and set a $120.00 price objective on shares of Billiontoone in a research report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Billiontoone presently has a consensus rating of “Moderate Buy” and an average target price of $129.57.

Billiontoone Stock Performance

The business has a 50-day moving average of $85.01. The firm has a market cap of $3.03 billion and a P/E ratio of 311.93.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, March 4th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.04 by $0.07. The business had revenue of $96.05 million during the quarter, compared to analyst estimates of $85.85 million. Billiontoone’s quarterly revenue was up 113.0% on a year-over-year basis.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors and hedge funds have recently made changes to their positions in BLLN. Green Alpha Advisors LLC acquired a new stake in shares of Billiontoone in the fourth quarter valued at about $436,000. FNY Investment Advisers LLC purchased a new position in Billiontoone in the fourth quarter valued at about $497,000. Massachusetts Financial Services Co. MA purchased a new position in Billiontoone in the fourth quarter valued at about $13,373,000. Baillie Gifford & Co. acquired a new stake in shares of Billiontoone during the 4th quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Billiontoone during the 4th quarter worth approximately $1,348,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.